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Objective: This study aimed to compare the diagnostic value of VIA with Pap smear in screening for
cervical cancer.
Materials and methods: In this cross-sectional study, 440 women who had eligibility criteria, in Kashan
city were assessed. All women underwent Pap smear test and then a visual inspection with acetic acid
and colposcopy-biopsy (Gold Standard). Then, the diagnostic value indices including the speciﬁcity,
sensitivity, positive and negative predictive values for the results of VIA and Pap smear were analyzed by
SPSS V16 software.
Results: Finding showed that 29.9% of women had abnormal Pap smear. The false positive rate of Pap
smear was 40.2%, and its false negative rate was 37.4%. For VIA, the false positive and false negative rates
were 21.2% and 4.6%. The sensitivity, speciﬁcity, NPV and PPV of Pap smear was 29.7%, 85.5%, 59.8%,
62.6%, and these values for VIA was 94.6%, 81.6%, 78.8%, 95.4% respectively. Combination of Pap smear
and VIA showed the sensitivity of 97.3% and 100% in low grade and high grade cervical lesions.
Conclusion: VIA has a higher sensitivity than Pap smear in detection of low and high grade cervical le-
sions, however, its speciﬁcity is less than Pap smears. Therefore it is recommended to use of VIA along
with Pap smear to reach a higher sensitivity.
© 2019 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cervical cancer is the fourth most common cancer in the world,
and included 7.9% of all women's cancer. 90% of this cancer occurs
in low-middle income countries [1]. In Iran, cervical cancer is the
second cancer after ovarian cancer and consists of 32.5% of all fe-
male cancers [2]. Over the past 50 years, mortality from this ma-
lignancy has clearly dropped in developed countries, largely due to
Pap smear screening test [3]. Despite this decline, the disease is still
a major cause of death among women, especially in developing
countries [4]. Also incidence rate of this cancer in Iran was 1.64 per
100,000 women in 2003 and increased to 2.61 per 100,000 women
in 2009 [5]. One of the methods for cervical cancer screening is Papzadeh-Kalahroudi).
Gynecology. Publishing services bsmear, but repeated screening for cervical cancer requires labora-
tories and well-trained, experienced staff and high costs, which are
not available in all developing countries and in all places [6,7]. Also,
the relatively long interval between doing the test and reaching the
patient's result in some cases leads to a lack of follow-up by the
patient. These problems has led to the development of several
cheap techniques, such as the use of magniﬁcation, visual inspec-
tion with acetic acid (VIA) or visual inspection with lugol iodine
(VILI), which can eliminate the barriers to screening by cytology.
The basis of VIA is that cervix with CIN lesions is whitened in the
presence of acetic acid. The beneﬁts of VIA are low cost. no need for
high technology, the result is immediate and is ready in1e2 min,
and can be done by health care providers in distance areas, which
makes VIA an excellent alternative method for Pap smear in
developing countries [8e10], but the low speciﬁcity of this method
has limited it [11].y Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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the diagnostic value of VIA and Pap smear in screening for cervical
cancer and different results have been obtained with regard to the
studied population and the methodology. In some studies, VIA has
been identiﬁed as an appropriate screening method [12e17] and in
others, given its low speciﬁcity, using these two methods simul-
taneously for cervical cancer screening has been recommended
[7,10,11,18e20].
Since cervical cancer is preventable and has a longer pre-
cancerous stage, so its screening is available and can be cured if
detected early. Since the sensitivity of the VIA method has been
very different in various studies, and according to the ﬁndings on
the usefulness of VIA in screening for cervical cancer compared to
pap smear, this study aimed to compare the diagnostic value of VIA
and pap smear in screening for cervical cancer in women referring
to Naghavi Hospital in Kashan, Iran.
Materials and methods
A cross-sectional study was performed on 440 women aged
20e65 years old in the Naghavi clinic at Kashan city in 2017. All
women participating in the study after examination of the cervix
underwent Pap smear test and then a visual inspection with acetic
acid. In the VIA method, the cervix was ﬁrst smeared with a 3%
acetic acid solution for 30e60 s and then was observed under
sufﬁcient light. The observation test with acetic acid is considered
to be positive when the whitening reaction (Aceto White) is clearly
seen (Fig. 1). Pap smear test were reported based on Bethesda
system. Positive Pap smear test refers to “unspeciﬁed abnormal
squamous cell” (ASCUS) lesions and more severe lesions (1 and 17).
Then, all subjects underwent colposcopy and biopsy (as a Gold
Standard method) by Fellowship of Women's Oncology who was
not aware of the results of VIA, if there was a suspected lesion bi-
opsy was taken, and in the absence of aceto white random biopsy
was taken from four cervical regions. If the result of the colposcopy
was normal and satisfactory, it was considered negative and in the
case of abnormal or unsatisfactory colposcopy for the person, bi-
opsy or endocervical curettage (ECC) was performed and a sample
was sent to the pathology department. If the report of pathology
indicates a CIN lesion or higher, it was considered as positive result.
All cytology slides and biopsy or ECC samples were reviewed by a
pathologist.
Inclusion and exclusion criteria
Inclusion criteria were sexually active and non-pregnant
women with no active disease of the cervix and no history of cer-
vical conization, cryo or other invasive cervical cancer treatment,
with no history of pre-invasive lesions or history of cervical cancer,
and exclusion criteria were not cooperating with other follow-up
steps.Fig. 1. VIA negative and positive pattern.Ethical considerations
This study was approved at the Ethics Committee of Kashan
University of Medical Sciences. Before the start of the study, the
consent of all individuals was obtained for participation in the
study and it was assured that their information would remain
conﬁdential.
Statistical analysis
After collecting data, frequency tables and statistical indices
were mapped according to the background variables. Then, the
diagnostic value indices including the speciﬁcity, sensitivity, posi-
tive and negative predictive values for the results of VIA, Pap smear
and combination of these two test were analyzed by SPSS V16
software. The level of signiﬁcance was lower than 0.05.
Results
In this study, 440 patients referred to gynecologic clinic of
Naghavi Hospital were evaluated. None of the patients were
excluded from the study. Patients were between the ages of 22 and
65 with an average age of 39. From 440 patients,79.1% had normal
Pap smear. There were 77 ASCUS, 12 LSILs, 2 HSILs and 1 ASC-H.
Totally, 21% of Pap smears were reported abnormal. The ﬁndings
showed that 50.5% of patients were VIA positive. In 58% of patients
colposcopy was normal. In 145 patients CIN1 and in 27 patients
CIN2 and in 12 patients CIN3 and in one patient SCC was reported.
In total, 42% of the colposcopic ﬁndings were positive.
Table 1 shows the false positive rate of VIA was 21.2% and its
false negative was 4.6%.
Findings showed that of 92 patients with positive Pap smear, 55
patients had positive colposcopy and biopsy. In other words, its
false positive and false negative was 40.2% and 37.4% respectively
(Table 2).
Table 3 indicates that the negative results of the VIA in 85.8% of
cases were in accordance with pap smear but positive results only
in 27.5% of cases were matched with pap smear. The Kappa coef-
ﬁcient was 0.132 (p ¼ 0.038).
The Sensitivity, speciﬁcity, NPV and PPV of Pap smear, VIA and
combination of Pap smear and VIA in screening for cervical cancer
are presented in Table 4.
Results of our data based on high grade cervical lesions (CIN II,
CINIII and carcinoma) are presented at Table 5.
Discussion
In this study, all women regardless of screening test results
underwent colposcopy and biopsy. Evaluation of screening tests in
different settings is important because the results of these tests are
valuable for screening policies.
In this study, it was found that 21% of patients had abnormal Pap
smear such as ASCUS lesions and higher lesions. In one study, 53.5%
of patients had an abnormal pap smear [6] that was more than theTable 1
Comparison of VIA Results and colposcopy.
VIA Colposcopy þ Biopsy*
Positive Negative Total
Positive 175 (78.8) 47 (21.2) 222 (100.0)
Negative 10 (4.6) 208 (95.4) 218 (100.0)
Total 185 (42.0) 255 (58.0) 440 (100.0)
*Data are presented as No and percent.
Table 2
Comparison of Pap smear results and colposcopy.
Pap Smear Colposcopy þ Biopsy*
Positive Negative Total
Positive 55 (59.8) 37 (40.2) 92 (100.0)
Negative 130 (37.4) 218 (62.6) 348 (100.0)
Total 185 (42.0) 255 (58.0) 440 (100.0)
*Data are presented as No and percent.
Table 3
Comparison of VIA and Pap smear results.
VIA Pap Smear*
Positive Negative Total
Positive 61 (27.5) 161 (72.5) 222 (100.0)
Negative 31 (14.2) 187 (85.8) 218 (100.0)
Total 92 (20.9) 348 (79.1) 440 (100.0)
*Data are presented as No and percent.
Table 4
Diagnostic value of Pap smear, VIA and combination of Pap smear and VIA.
Test Sensitivity speciﬁcity PPV NPV
VIA 94.6% 81.6% 78.8% 95.4%
Pap smear 29.7% 85.5% 59.8% 62.6%
Pap smear and VIA 97.3% 71.4% 71.1% 92.4%
Table 5
Diagnostic value of Pap smear, VIA and combination of Pap smear and VIA in High
grade CIN.
Test Sensitivity speciﬁcity PPV NPV
VIA 100% 54.5% 18% 100%
Pap smear 45% 81.5% 19.6% 93.7%
Pap smear and VIA 100% 46.8% 15.8% 100%
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considered abnormal in that study. Among the cases of abnormal
Pap smear, most reported cases include ASCUS with 17% and LSIL,
HSIL, ASC-H 2.7%, 0.5%, 0.2% respectively that are more than rates
(13.5%) reported by recent study [6].
In 51% of pap smears, have been reported varying degrees of
inﬂammation frommild to severe that wasmore than results of one
study (38.5%) [6], which could be due to differences in the study
population. The ﬁndings showed that VIA was positive in 50.5%.
This is reported 41.5% in one study [6], but in comparison to the
other studies, is higher [15,21,22], which is probably due to the use
of different criteria in the positive view of VIA in these studies or
the difference in the population of screened women. For example,
in the study of jeronimo et al. CIN was not considered positive or in
the study of Sankaranarayanan et al. VIA divided into two groups
(þ) and (þþ), which only consider (þþ) as positive. But in this
study both VIA þ and VIA þþ are considered to be positive.
The ﬁndings of the study on colposcopy showed that 58% of
subjects had normal colposcopy and other lesions including CIN1,
CIN2, CIN3 and SCCwere reported 33%, 6.1%, 2.7%, 0.2% respectively.
In recent study [22] normal colposcopy was seen in 38% of patients
and CIN1, CIN2, CIN3 and SCC were reported 28%, 19%, 10% and 5%,
respectively.
The results of this study showed that the false positive rate of
VIAwas 21.2% and its false negative was 4.6%. The false positive rate
in several studies were reported 29.4%, 67.4% and 9.1%, and false
negative were reported 12%, 20% and 6.8% [6,7,11]. All of these
values were different from the present study which could bedifference in the studied population. The ﬁndings show that
inﬂammation and infection increase the false-positive VIA by up to
two times [23].
In patients with positive VIA, 27.5% had positive Pap smear and
72.5% were Pap smear negative. For patients with VIA negative,
14.2% had positive Pap smear and in 85.8% of patients, Pap smear
was reported negative. In one study 40% of the patients with pos-
itive VIA were positive for Pap smear and 24.5% despite having
positive VIA, Pap smears were negative. 12.9% of patients with
negative VIA, had positive Pap smear and at 22.5% of patients both
VIA and Pap smear were reported negative [22].
In this study, the false positive rate (40.2%) of Pap smear was
higher than other studies that varied from 0% to 22.2% [6,7,11]. High
levels of false positives can lead to additional diagnostic and ther-
apeutic procedures for patients. Also in this study, the false nega-
tive rate of Pap smear was 37.4%, which is lower than most of the
studies that have been reported a range of 13.5%e74.2% [6,7,11]. A
high false negative level can lead to a lack of early detection of
patients and a delay in treatment.
The ﬁndings showed that VIA had a higher sensitivity than Pap
smear, but its speciﬁcity was less than Pap smear. These values are
higher than most studies in terms of sensitivity and speciﬁcity. In
various studies, the sensitivity of VIA was between 62.5% and 96%,
and its speciﬁcity was between 32.5% and 98.8%. Also, Pap smear
sensitivity in different studies has been reported between
10% and 75% and its speciﬁcity between 42% and 100%
[6,7,11,12,19,22,24,25].
In our study, Pap smear had a higher speciﬁcity than some
studies, but its sensitivity was less than many studies. In all of these
studies, apart from two studies, Pap smear speciﬁcity is reported
more than VIA [11,19]. Overall, it can be said that in the present
study, VIA has a higher sensitivity than Pap smear, but its speci-
ﬁcity, as the same asmost studies is less than Pap smear. The reason
for low level of VIA speciﬁcity in the present study was that all
white lesions were considered positive and that the presence of
cervical polyps, inﬂammation and metaplasia, could also result in
false positive results for VIA.
In this study, the PPV of VIA was higher than Pap smear, but the
NPV for Pap smear was higher than the VIA. In various studies, the
PPV of VIA has been reported between 8.3% and 90.9%
[6,7,11,12,19,21,22,25,26].In our study, PPV for VIAwas similar to the
Eftekhar et al. and Khan et al. studies [11,25]. The PPV of Pap
smear has also been reported between 6.3% and 100%
[6,7,11,12,19,21,22,25,26], that our ﬁndings are almost similar to the
Gupta et al. study.
In various studies, the NPV of VIA were reported between 66.6%
and 99% [6,7,11,12,19,25,26]. Our ﬁndings are lower than
other studies. The NPV of the pap smear varied from 43 to 96%
[6,7,11,12,19,25,26]. The NPV in our study is almost similar to
Keshavarzi et al. study [12].
Combination of Pap smear and VIA showed the higher sensi-
tivity than VIA or Pap smear alone. In one study the sensitivity of
combination of VIA and Pap smear were reported 70% [11]. In that
study like ours, the sensitivity of VIA was higher than Pap smear
(96% and 10% respectively).
VIA was 100% sensitive for detection of high grade lesions but,
Pap smear had 45% sensitivity. Combination of these two tests was
resulted in 100% sensitivity for CIN II and higher. In one study the
VIA sensitivity and speciﬁcity for detection of high grade lesions
was 87.5% and 78.8% respectively [27].
The reason for these variations in the diagnostic value of Pap
smear and VIA in different studies may be due to considering
different diagnostic criteria, difference in considering the positive
tests results and differences in the studied population.The ﬁndings
of this study and other studies indicate that the main limitation of
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and performing more colposcopic procedure in patients. On the
other hand, it is a low cost, simpler and easier method than Pap
smear, and does not require complicated laboratory facilities.
Therefore it can be recommended for primary screening program in
low resource settings. In a study in ﬁve low resource countries,
direct cost for Pap smear was twofold of VIA and direct cost of
colposcopy and biopsy was approximately 9 fold of Pap smear [28].
The strengths of this study are performing colposcopy and bi-
opsy in all patients, which led to an accurate report of sensitivity
and speciﬁcity of Pap smear and VIA. The high false negative rates
of VIA limit it as a screening test. Therefore, it is advisable to design
more studies with different VIA positive protocols in order to
reduce the amount of colposcopy and ﬁnal costs. It is recommended
to reduce errors and increase the accuracy of results, more studies
with higher sample size andmulti-centered studies would be done.
VIA is a sensitive, practical and low-cost test in detection of low
grade and high grade cervical lesion, but has a lower speciﬁcity
than Pap smear. Therefore, as the test used in screening should have
good sensitivity and speciﬁcity, it is more valuable to use of VIA in
cervical cancer screening. Use of VIA along with Pap smear resulted
a higher sensitivity for detection of cervical lesions.
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